bluebird bio, Inc. (NASDAQ:BLUE) insider Eric Sullivan sold 861 shares of the company’s stock in a transaction on Friday, August 4th. The shares were sold at an average price of $93.83, for a total value of $80,787.63. Following the completion of the transaction, the insider now owns 5,924 shares of the company’s stock, valued at $555,848.92. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Eric Sullivan also recently made the following trade(s):

  • On Thursday, June 29th, Eric Sullivan sold 6,787 shares of bluebird bio stock. The shares were sold at an average price of $108.96, for a total value of $739,511.52.

bluebird bio, Inc. (NASDAQ BLUE) traded up 3.761% on Monday, reaching $98.625. The company’s stock had a trading volume of 613,084 shares. The company has a 50-day moving average price of $102.86 and a 200 day moving average price of $88.98. The company’s market cap is $4.49 billion. bluebird bio, Inc. has a 12 month low of $37.05 and a 12 month high of $123.75.

bluebird bio (NASDAQ:BLUE) last announced its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($1.73) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.66) by $0.07. The company had revenue of $16.70 million during the quarter, compared to analyst estimates of $6.29 million. bluebird bio had a negative net margin of 1,080.59% and a negative return on equity of 32.19%. bluebird bio’s revenue was up 977.4% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.59) earnings per share. On average, equities research analysts anticipate that bluebird bio, Inc. will post ($6.69) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This story was published by American Banking News and is the property of of American Banking News. If you are accessing this story on another site, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/08/07/bluebird-bio-inc-nasdaqblue-insider-sells-80787-63-in-stock.html.

A number of brokerages recently commented on BLUE. Morgan Stanley upped their target price on bluebird bio from $103.00 to $105.00 and gave the company an “equal weight” rating in a research note on Monday. BMO Capital Markets restated a “buy” rating and issued a $108.00 target price on shares of bluebird bio in a research note on Friday. BidaskClub lowered bluebird bio from a “hold” rating to a “sell” rating in a research note on Wednesday, August 2nd. Sanford C. Bernstein began coverage on bluebird bio in a research note on Thursday, July 27th. They issued a “market perform” rating and a $109.00 target price for the company. Finally, Cantor Fitzgerald restated a “sell” rating and issued a $39.00 target price on shares of bluebird bio in a research note on Monday, July 24th. Three investment analysts have rated the stock with a sell rating, seven have issued a hold rating and eleven have assigned a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $100.66.

Institutional investors have recently made changes to their positions in the stock. Bank of Montreal Can boosted its position in shares of bluebird bio by 118.9% in the second quarter. Bank of Montreal Can now owns 1,677 shares of the biotechnology company’s stock valued at $176,000 after buying an additional 911 shares in the last quarter. Turner Investments LLC bought a new position in shares of bluebird bio during the second quarter valued at $184,000. SG Americas Securities LLC boosted its position in shares of bluebird bio by 17.9% in the second quarter. SG Americas Securities LLC now owns 1,945 shares of the biotechnology company’s stock valued at $204,000 after buying an additional 295 shares in the last quarter. Affinity Investment Advisors LLC bought a new position in shares of bluebird bio during the second quarter valued at $246,000. Finally, First Mercantile Trust Co. boosted its position in shares of bluebird bio by 14.4% in the first quarter. First Mercantile Trust Co. now owns 2,897 shares of the biotechnology company’s stock valued at $263,000 after buying an additional 365 shares in the last quarter.

bluebird bio Company Profile

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

Insider Buying and Selling by Quarter for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.